Inflammasome Activation Mechanisms in Liver Pathophysiology

The inflammasome is an innate immune machinery that senses cellular stress and injury signals in the liver, assembling to activate caspase-1 and drive maturation of interleukin-1β and interleukin-18. In both chronic and acute liver disorders, including non-alcoholic fatty liver disease (NAFLD), steatohepatitis (NASH), viral hepatitis, alcoholic liver disease and autoimmune hepatitis, multiple cell types—hepatocytes, Kupffer cells, hepatic stellate cells and infiltrating immune cells—trigger inflammasome assembly in response to pathogen-associated or damage-associated molecular patterns. Activation of the NLRP3 inflammasome is the most extensively studied pathway, linking metabolic dysfunction, mitochondrial stress and endoplasmic reticulum perturbations to proinflammatory cytokine release and gasdermin D-mediated pyroptosis. The ensuing cytokine storm and programmed cell death promote hepatic inflammation, fibrogenesis and, ultimately, organ dysfunction. Recent advances highlight regulatory circuits involving transcription factors, autophagy, lipid sensing and cell-type-specific scaffolding proteins that fine-tune inflammasome activity. A deeper understanding of these interconnected mechanisms offers avenues to intercept inflammation-driven progression from steatosis to fibrosis, cirrhosis and liver failure.

Research from Nature Portfolio

Emerging foundational work has demonstrated that small-molecule and natural compounds can directly modulate inflammasome activity in diet-induced models of fatty liver disease. Oral administration of a sulforaphane-based inhibitor was shown to restore mitochondrial homeostasis and activate autophagy, thereby suppressing NLRP3 assembly and caspase-1 cleavage in hepatocytes and preventing high-fat diet-induced steatosis and biochemical markers of liver injury. In parallel, investigations into plant-derived polyphenols revealed that salvianolic acid A ameliorates lipid accumulation and inflammatory signalling by down-regulating TXNIP expression and blocking its interaction with NLRP3, as well as inhibiting the carbohydrate response element-binding protein pathway. These insights establish proof of principle that targeting upstream regulators of inflammasome activation can protect against hepatic lipid overload and inflammation.

Inflammasome Activation Mechanisms in Liver Pathophysiology publication trend

The graph below shows the total number of articles in inflammasome activation mechanisms in liver pathophysiology across all publications each year (not limited to Nature Index journals).

Technical terms

Inflammasome: A multi-protein complex that recognises danger signals and activates inflammatory caspase-1.

NLRP3: A cytosolic receptor that nucleates inflammasome assembly in response to metabolic or microbial stress.

Pyroptosis: A form of lytic programmed cell death driven by gasdermin D pore formation and cytokine release.

Gasdermin D: The executor protein cleaved by caspase-1 to form membrane pores and induce pyroptosis.

Toll-like receptor: A family of cell-surface receptors that detect microbial or damage signals and initiate immune signalling.

References

1. A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet. Scientific Reports (2016).
2. New insights into salvianolic acid A action: Regulation of the TXNIP/NLRP3 and TXNIP/ChREBP pathways ameliorates HFD-induced NAFLD in rats. Scientific Reports (2016).
3. Hepatic Zbtb18 (Zinc Finger and BTB Domain Containing 18) alleviates hepatic steatohepatitis via FXR (Farnesoid X Receptor). Signal Transduction and Targeted Therapy (2024).
4. Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation. Journal of Hepatology (2024).
5. PD‐1+CD8+ T Cell‐Mediated Hepatocyte Pyroptosis Promotes Progression of Murine Autoimmune Liver Disease. Advanced Science (2024).